TransMedics (TMDX) Common Equity (2018 - 2026)

TransMedics has reported Common Equity for 9 years, with the latest figure at $494.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 85.5% year-over-year to $494.0 million; the trailing twelve-month figure through Mar 2026 stood at $494.0 million (up 85.5% YoY), and the FY2025 full-year result was $473.1 million, up 106.95% from the prior year.
• Common Equity for Q1 2026 stood at $494.0 million, up from $473.1 million in the prior quarter.
• The five-year high for Common Equity was $494.0 million in Q1 2026, with the low at $50.9 million in Q2 2022.
• Average Common Equity over 5 years is $222.5 million, with a median of $189.9 million recorded in 2024.
• Year-over-year, Common Equity slumped 42.78% in 2022 and jumped 221.52% in 2023.
• Tracing TMDX's Common Equity over 5 years: stood at $187.4 million in 2022, then fell by 26.78% to $137.2 million in 2023, then surged by 66.62% to $228.6 million in 2024, then jumped by 106.95% to $473.1 million in 2025, then grew by 4.42% to $494.0 million in 2026.
• The last three Common Equity figures came in at $494.0 million (Q1 2026), $473.1 million (Q4 2025), and $355.2 million (Q3 2025), per Business Quant data.

Peer Comparison